Scales to assess psychosis in Parkinson's disease: Critique and recommendations
Identifieur interne : 000362 ( Main/Corpus ); précédent : 000361; suivant : 000363Scales to assess psychosis in Parkinson's disease: Critique and recommendations
Auteurs : Hubert H. Fernandez ; Dag Aarsland ; Gilles Fénelon ; Joseph H. Friedman ; Laura Marsh ; Alexander I. Tröster ; Werner Poewe ; Olivier Rascol ; Cristina Sampaio ; Glenn T. Stebbins ; Christopher G. GoetzSource :
- Movement Disorders [ 0885-3185 ] ; 2008-03-15.
English descriptors
- KwdEn :
Abstract
Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer‐reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as “recommended” or “suggested” based on the fulfilling‐defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21875
Links to Exploration step
ISTEX:C11CBCBE67A473C4012FBCE7C78803B7B64F14BBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Scales to assess psychosis in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name><affiliation><mods:affiliation>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Stavanger University Hospital, Centre for Clinical Neuroscience Research, Stavanger, Norway</mods:affiliation></affiliation></author><author><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fénelon">Gilles Fénelon</name><affiliation><mods:affiliation>Department of Neurology, Hôpital Henri‐Mondor, Crétil, France</mods:affiliation></affiliation></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation><mods:affiliation>Department of Clinical Neuroscience, Brown University Medical School, Providence, Rhode Island, USA</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Tröster">Alexander I. Tröster</name><affiliation><mods:affiliation>Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C11CBCBE67A473C4012FBCE7C78803B7B64F14BB</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21875</idno><idno type="url">https://api.istex.fr/document/C11CBCBE67A473C4012FBCE7C78803B7B64F14BB/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000362</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Scales to assess psychosis in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name><affiliation><mods:affiliation>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Stavanger University Hospital, Centre for Clinical Neuroscience Research, Stavanger, Norway</mods:affiliation></affiliation></author><author><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fénelon">Gilles Fénelon</name><affiliation><mods:affiliation>Department of Neurology, Hôpital Henri‐Mondor, Crétil, France</mods:affiliation></affiliation></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation><mods:affiliation>Department of Clinical Neuroscience, Brown University Medical School, Providence, Rhode Island, USA</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Tröster">Alexander I. Tröster</name><affiliation><mods:affiliation>Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-03-15">2008-03-15</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="484">484</biblScope><biblScope unit="page" to="500">500</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C11CBCBE67A473C4012FBCE7C78803B7B64F14BB</idno><idno type="DOI">10.1002/mds.21875</idno><idno type="ArticleID">MDS21875</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson</term><term>delusion</term><term>hallucination</term><term>psychosis</term><term>scales</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer‐reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as “recommended” or “suggested” based on the fulfilling‐defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Hubert H. Fernandez MD</name><affiliations><json:string>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida, USA</json:string></affiliations></json:item><json:item><name>Dag Aarsland MD</name><affiliations><json:string>Stavanger University Hospital, Centre for Clinical Neuroscience Research, Stavanger, Norway</json:string></affiliations></json:item><json:item><name>Gilles Fénelon MD</name><affiliations><json:string>Department of Neurology, Hôpital Henri‐Mondor, Crétil, France</json:string></affiliations></json:item><json:item><name>Joseph H. Friedman MD</name><affiliations><json:string>Department of Clinical Neuroscience, Brown University Medical School, Providence, Rhode Island, USA</json:string></affiliations></json:item><json:item><name>Laura Marsh MD</name><affiliations><json:string>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</json:string></affiliations></json:item><json:item><name>Alexander I. Tröster PhD</name><affiliations><json:string>Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine, Toulouse, France</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD</name><affiliations><json:string>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins PhD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>psychosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>scales</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hallucination</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>delusion</value></json:item></subject><articleId><json:string>MDS21875</json:string></articleId><language><json:string>eng</json:string></language><abstract>Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer‐reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as “recommended” or “suggested” based on the fulfilling‐defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1696</abstractCharCount><pdfWordCount>11693</pdfWordCount><pdfCharCount>75007</pdfCharCount><pdfPageCount>17</pdfPageCount><abstractWordCount>256</abstractWordCount></qualityIndicators><title>Scales to assess psychosis in Parkinson's disease: Critique and recommendations</title><genre><json:string>article</json:string></genre><host><volume>23</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>17</total><last>500</last><first>484</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.21875</json:string></doi><id>C11CBCBE67A473C4012FBCE7C78803B7B64F14BB</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C11CBCBE67A473C4012FBCE7C78803B7B64F14BB/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C11CBCBE67A473C4012FBCE7C78803B7B64F14BB/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C11CBCBE67A473C4012FBCE7C78803B7B64F14BB/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Scales to assess psychosis in Parkinson's disease: Critique and recommendations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Scales to assess psychosis in Parkinson's disease: Critique and recommendations</title><author><persName><forename type="first">Hubert H.</forename><surname>Fernandez</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, McKnight Brain Institute/University of Florida, 100 S. Newell Drive, PO Box 100236, Gainesville, FL 32611</p></note><affiliation>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida, USA</affiliation></author><author><persName><forename type="first">Dag</forename><surname>Aarsland</surname></persName><roleName type="degree">MD</roleName><affiliation>Stavanger University Hospital, Centre for Clinical Neuroscience Research, Stavanger, Norway</affiliation></author><author><persName><forename type="first">Gilles</forename><surname>Fénelon</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Hôpital Henri‐Mondor, Crétil, France</affiliation></author><author><persName><forename type="first">Joseph H.</forename><surname>Friedman</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Clinical Neuroscience, Brown University Medical School, Providence, Rhode Island, USA</affiliation></author><author><persName><forename type="first">Laura</forename><surname>Marsh</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</affiliation></author><author><persName><forename type="first">Alexander I.</forename><surname>Tröster</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine, Toulouse, France</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal</affiliation></author><author><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-03-15"></date><biblScope unit="volume">23</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="484">484</biblScope><biblScope unit="page" to="500">500</biblScope></imprint></monogr><idno type="istex">C11CBCBE67A473C4012FBCE7C78803B7B64F14BB</idno><idno type="DOI">10.1002/mds.21875</idno><idno type="ArticleID">MDS21875</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer‐reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as “recommended” or “suggested” based on the fulfilling‐defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson</term></item><item><term>psychosis</term></item><item><term>scales</term></item><item><term>hallucination</term></item><item><term>delusion</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-05-03">Received</change><change when="2007-10-28">Registration</change><change when="2008-03-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C11CBCBE67A473C4012FBCE7C78803B7B64F14BB/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v23:4</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2008-03-15">15 March 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="30" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21875</doi><idGroup><id type="unit" value="MDS21875"></id></idGroup><countGroup><count type="pageTotal" number="17"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Task Force Report</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-05-03"></event><event type="manuscriptRevised" date="2007-08-14"></event><event type="manuscriptAccepted" date="2007-10-28"></event><event type="publishedOnlineEarlyUnpaginated" date="2008-01-03"></event><event type="firstOnline" date="2008-01-03"></event><event type="publishedOnlineFinalForm" date="2008-03-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-01"></event></eventGroup><numberingGroup><numbering type="pageFirst">484</numbering><numbering type="pageLast">500</numbering></numberingGroup><correspondenceTo>Department of Neurology, McKnight Brain Institute/University of Florida, 100 S. Newell Drive, PO Box 100236, Gainesville, FL 32611</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21875.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="85"></count><count type="wordTotal" number="12995"></count></countGroup><titleGroup><title type="main" xml:lang="en">Scales to assess psychosis in Parkinson's disease: Critique and recommendations</title><title type="short" xml:lang="en">Scales to Assess Psychosis in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Hubert H.</givenNames><familyName>Fernandez</familyName><degrees>MD</degrees></personName><contactDetails><email>fernandez@neurology.ufl.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Dag</givenNames><familyName>Aarsland</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Gilles</givenNames><familyName>Fénelon</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Joseph H.</givenNames><familyName>Friedman</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Laura</givenNames><familyName>Marsh</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Alexander I.</givenNames><familyName>Tröster</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="NO" type="organization"><unparsedAffiliation>Stavanger University Hospital, Centre for Clinical Neuroscience Research, Stavanger, Norway</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, Hôpital Henri‐Mondor, Crétil, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Clinical Neuroscience, Brown University Medical School, Providence, Rhode Island, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="PT" type="organization"><unparsedAffiliation>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson</keyword><keyword xml:id="kwd2">psychosis</keyword><keyword xml:id="kwd3">scales</keyword><keyword xml:id="kwd4">hallucination</keyword><keyword xml:id="kwd5">delusion</keyword></keywordGroup><supportingInformation><p> This article contains supplementary material available via the Internet at <url href="http://www.interscience.wiley.com/jpages/0885-3185/suppmat"> http://www.interscience.wiley.com/jpages/0885‐3185/suppmat </url> . </p></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer‐reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as “recommended” or “suggested” based on the fulfilling‐defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Scales to assess psychosis in Parkinson's disease: Critique and recommendations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Scales to Assess Psychosis in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Scales to assess psychosis in Parkinson's disease: Critique and recommendations</title></titleInfo><name type="personal"><namePart type="given">Hubert H.</namePart><namePart type="family">Fernandez</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida, USA</affiliation><description>Correspondence: Department of Neurology, McKnight Brain Institute/University of Florida, 100 S. Newell Drive, PO Box 100236, Gainesville, FL 32611</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dag</namePart><namePart type="family">Aarsland</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Stavanger University Hospital, Centre for Clinical Neuroscience Research, Stavanger, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gilles</namePart><namePart type="family">Fénelon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Hôpital Henri‐Mondor, Crétil, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph H.</namePart><namePart type="family">Friedman</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Clinical Neuroscience, Brown University Medical School, Providence, Rhode Island, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Marsh</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexander I.</namePart><namePart type="family">Tröster</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-03-15</dateIssued><dateCaptured encoding="w3cdtf">2007-05-03</dateCaptured><dateValid encoding="w3cdtf">2007-10-28</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">4</extent><extent unit="references">85</extent><extent unit="words">12995</extent></physicalDescription><abstract lang="en">Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer‐reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as “recommended” or “suggested” based on the fulfilling‐defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson</topic><topic>psychosis</topic><topic>scales</topic><topic>hallucination</topic><topic>delusion</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><note type="content"> This article contains supplementary material available via the Internet at http://www.interscience.wiley.com/jpages/0885‐3185/suppmat .</note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>484</start><end>500</end><total>17</total></extent></part></relatedItem><identifier type="istex">C11CBCBE67A473C4012FBCE7C78803B7B64F14BB</identifier><identifier type="DOI">10.1002/mds.21875</identifier><identifier type="ArticleID">MDS21875</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000362 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000362 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:C11CBCBE67A473C4012FBCE7C78803B7B64F14BB
|texte= Scales to assess psychosis in Parkinson's disease: Critique and recommendations
}}
| This area was generated with Dilib version V0.6.23. |  |